NextVivo Launches from Khosla Ventures to Transform Drug Development Using Next-Generation Organoid Platform

NextVivo emerged from stealth with $7.9M in financing led by Khosla Ventures, with participation from Alexandria Venture Investments with plans to develop the first organoid platform able to generate and test therapies in immune-competent human-derived models.